Cost-effectiveness of different strategies for the treatment of moderate-to-severe ulcerative colitis

B Wu, Z Wang, Q Zhang - Inflammatory Bowel Diseases, 2018 - academic.oup.com
Background Knowledge regarding the economic outcomes of anti-tumour necrosis factor-α
(anti-TNFα) and oral Janus kinase inhibitor (JAKi) therapies for the treatment of ulcerative …
被引用次数：27 相关文章

Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.

B Wu, Z Wang, Q Zhang - Inflammatory Bowel Diseases, 2018 - europepmc.org
Background: Knowledge regarding the economic outcomes of anti-tumour necrosis factor-α
(anti-TNFα) and oral Janus kinase inhibitor (JAKi) therapies for the treatment of ulcerative …

Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis

B Wu, Z Wang, Q Zhang - Inflammatory bowel diseases, 2018 - pubmed.ncbi.nlm.nih.gov
Background Knowledge regarding the economic outcomes of anti-tumour necrosis factor-α
(anti-TNFα) and oral Janus kinase inhibitor (JAKi) therapies for the treatment of ulcerative …

Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis

B Wu, Z Wang, Q Zhang - Inflammatory Bowel Diseases, 2018 - academic.oup.com
Background Knowledge regarding the economic outcomes of anti-tumour necrosis factor-α
(anti-TNFα) and oral Janus kinase inhibitor (JAKi) therapies for the treatment of ulcerative …